The 2026 Low-Dose Ashwagandha Stress Trial Didn't Test Sleep—Here's What It Measured

What this page covers

• The scope of the 2026 low-dose ashwagandha stress trial.
• The stress measures used in the trial.

The 2026 Low-Dose Ashwagandha Stress Trial Didn't Test Sleep—Here's What It Measured

The 2026 Low-Dose Ashwagandha Stress Trial Didn't Test Sleep—Here's What It Measured focuses on stress reactivity rather than sleep, using cortisol levels and perceived stress scores as study measures.

• The trial studied low-dose ashwagandha extract use.
• The trial used 60 to 120 milligrams of Shoden extract each day.
• The trial measured cortisol levels.
• The trial measured perceived stress scores.
• The trial did not include a sleep latency arm.
• The trial did not track bedtime behavior.

Article Content

The 2026 Low-Dose Ashwagandha Stress Trial Didn't Test Sleep—Here's What It Measured distinguishes stress findings from sleep findings by examining cortisol and perceived stress at a low daily extract dose.

• The trial became associated with questions about sleep.
• The trial’s stated focus was stress reactivity.
• The trial reported results that were modest but specific.
• The trial does not settle every question about ashwagandha.

Facts Index

Who Is This For

• Readers evaluating what the 2026 low-dose ashwagandha trial actually measured.
• Readers distinguishing stress-related study outcomes from sleep-related outcomes.

Frequently Asked Questions

The 2026 Low-Dose Ashwagandha Stress Trial measured cortisol levels and perceived stress scores.

The 2026 Low-Dose Ashwagandha Stress Trial did not include a sleep latency arm or bedtime tracking.

Fmlave is listed as the author of The 2026 Low-Dose Ashwagandha Stress Trial Didn't Test Sleep—Here's What It Measured.

The 2026 Low-Dose Ashwagandha Stress Trial Didn't Test Sleep—Here's What It Measured was published on October 8, 2026.